Sunsho Pharmaceutical Co.,Ltd.

Sunsho Pharmaceutical Co. , Ltd. is dedicated to developing and manufacturing diverse capsule formulations, focusing on health and wellness products tailored for pharmaceutical and dietary supplement markets. Founded in 1993, Sunsho Pharmaceutical Co.

, Ltd. is located in Fuji, Japan. The company specializes in capsule formulations, catering to businesses seeking quality production solutions. It has completed 2 total deals, with the most recent deal occurring on December 17, 2021.

The leadership team includes ARIF KHAN and others, contributing to the company's direction in the industry. Sunsho Pharmaceutical Co. , Ltd. primarily specializes in the development and manufacturing of advanced capsule formulations tailored for the health and wellness sector.

Their core product offerings include various forms of capsules such as soft capsules, seamless capsules, hard capsules, tablets, and granules, designed to address diverse consumer needs in dietary supplements, pharmaceuticals, and functional foods. The company's proprietary technologies, including the UniORV® system, enhance product efficacy and consumer experience, allowing for customized solutions that meet specific health requirements. Sunsho Pharmaceutical serves a wide range of customers, including businesses in Asia, India, and the Middle East, focusing on partnerships with dietary supplement manufacturers and pharmaceutical companies seeking high-quality production capabilities. With an emphasis on innovation and quality, their products are designed to meet the demands of health-conscious consumers across these markets.

Sunsho Pharmaceutical Co. , Ltd. 's revenue generation model is primarily structured around B2B transactions, where it establishes partnerships with manufacturers and retailers in the dietary supplement and pharmaceutical industries. These partnerships often involve contract manufacturing agreements, allowing clients to utilize Sunsho’s expertise in product formulation and production.

By providing tailored solutions, the company enhances its clients' product offerings, which in turn drives sales and market penetration. While specific pricing structures for their products are proprietary, the company focuses on delivering high-value products that align with industry standards, thereby ensuring competitive positioning in the global market. Their flagship products, particularly those utilizing innovative formulations and technologies, are key drivers of client engagement and sales within the health and wellness sector. In December 2021, TOWA PHARMACEUTICAL agreed to fully acquire Sansei Pharmaceutical Co.

, Ltd. from Carlyle Group, which is expected to be completed by February 2022. This transaction is anticipated to support the next phase of growth for Sansei Pharmaceutical. Sunsho is likely to leverage this change to enhance its product portfolio and market position moving forward.